Navigation Links
Galmed Pharmaceuticals Reports First Half 2014 Financial Results
Date:7/25/2014

utilizing its proprietary first-in-class family of synthetic fatty-acid/bile-acid conjugates, or FABACs. Galmed believes that its product candidate, aramchol, has the potential to be a disease modifying treatment for fatty liver disorders, including NASH, which is a chronic disease that Galmed believes constitutes a large unmet medical need.

Forward-Looking Statements
This press release includes forward-looking statements. Such forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Applicable risks and uncertainties include those identified under the heading "Risk Factors" included in the registration statement on Form F-1 (File No. 333 -193792), initially filed with the Securities and Exchange Commission, or the SEC, on February 6, 2014 and declared effective by the SEC on March 12, 2014, and in other filings that Galmed has made and may make with the SEC in the future. The forward-looking statements contained in this press release reflect Galmed's current views with respect to future events, and Galmed does not undertake and specifically disclaims any obligation to update any forward-looking statements.

 GALMED PHARMACEUTICALS LTD.Condensed Consolidated Balance SheetsU.S. Dollars in thousands, except share data and per share dataSuccessorPredecessorAs of
June 30, 2014As of
December 31,
2013UnauditedAuditedAssetsCurrent AssetsCash and cash equivalents$
37,399

$
37
Other accounts receivable61

16Total current assets37,640

153Property and equipment, net24

13Total assets$
37,484'/>"/>

SOURCE Galmed Pharmaceuticals Ltd.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
2. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
3. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
4. Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
5. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
6. Acumen Pharmaceuticals Regains Worldwide Rights to Anti-ADDL Antibody Therapeutics and Diagnostics for Alzheimers Disease From Merck
7. Inspiration Biopharmaceuticals Moves Corporate Headquarters to Cambridge, Massachusetts
8. Ampio Pharmaceuticals Awarded Canadian Composition of Matter Patent That Strengthens IP Protection for Its Key Drug Ampion™
9. Amylin Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
10. Inovio Pharmaceuticals Promotes Niranjan Sardesai to Chief Operating Officer
11. Keryx Biopharmaceuticals to Present at JP Morgans 30th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... An interdisciplinary team of researchers led by Northeastern ... constructing precise inter-nanotube junctions and a variety of ... is facile and easily scalable, which will allow ... nanotube networks for use in applications ranging from ... everything from cars to sports equipment. , Their ...
(Date:9/15/2014)... 2014 Zymo Research Corp., has announced the ... safe ambient temperature storage and transport of infectious ... of agents in such samples is completely inactivated ... the viral nucleic acids for subsequent analyses.  With ... in West Africa and ...
(Date:9/15/2014)... Research and Markets has announced the addition of ... by Technology, by Application - Global Forecast to 2018" ... (WES) is next-generation technology used for strategically sequencing the coding ... is the total of all exons of an organism, represents ... into proteins after translation. It is responsible for the occurrence ...
(Date:9/15/2014)... CA (PRWEB) September 15, 2014 ... term implantable silicones for the medical device and ... silicone gel for the implantable medical device market. ... unique crosslink technology delivering a silicone gel with ... The Dual Matrix technology consists of two crosslinked ...
Breaking Biology Technology:Northeastern University Researchers Develop Novel Method for Working with Nanotubes 2Safe storage and transport of Ebola, Mers-CoV, and other viruses: Groundbreaking viral inactivation solution capable of preserving nucleic acids 2Safe storage and transport of Ebola, Mers-CoV, and other viruses: Groundbreaking viral inactivation solution capable of preserving nucleic acids 3Global Whole Exome Sequencing (Systems, Kits, Library Preparation, Target Enrichment) Market by Product, by Services, by Technology, by Application - Forecast to 2018 2Global Whole Exome Sequencing (Systems, Kits, Library Preparation, Target Enrichment) Market by Product, by Services, by Technology, by Application - Forecast to 2018 3Applied Silicone Launches Silicone Gel System with Dual Matrix Technology 2
... TRIANGLE PARK, N.C., Dec. 14, 2010 Talecris Biotherapeutics Holdings ... jury in the General Court of Justice, Superior Court Division, ... 2010 in the amount of $37 million in favor of ... Resources, Inc., in a breach of contract claim. ...
... available in Spanish . The researchers decided ... which mechanisms are used by plants when they extract water ... of mangrove swamps, for example, the plants are able to ... the osmotic pressure should make quite the opposite happen", explains ...
... Utilizing a century-old phenomenon discovered in St. Paul,s Cathedral, ... the first time, highly collimated unidirectional microlasers. The ... in Hamamatsu City, Japan, and the Institute of Theoretical ... has a wide range of new applications in photonics ...
Cached Biology Technology:Talecris Biotherapeutics Announces Jury Verdict in Contract Dispute 2A study analyzes the movement of tree sap 2Capasso lab demonstrates highly unidirectional 'whispering gallery' microlasers 2
(Date:9/15/2014)... , , , , , ... , , , , ... eight genetically distinct disorders, each with its own set of symptoms. The finding could be a first... , ... , , , , , ... , , , , , , ...
(Date:9/15/2014)... This news release is available in German . ... as a substitute for the fossil energy carrier natural ... a sustainable energy supply. Nevertheless, a consequent market penetration ... and transnational frame conditions. Scientists of the Helmholtz Centre ... Centre (DBFZ) and other Members of the IEA Task ...
(Date:9/12/2014)... Ireland , September 12, 2014 /PRNewswire/ ... Markets ( http://www.researchandmarkets.com/research/trs4c7/global ) has announced the ... Industry Report 2014" report to their ... Lock Industry Report 2014 is a professional ... of the global fingerprint lock industry. , ...
Breaking Biology News(10 mins):Schizophrenia not a single disease but multiple genetically distinct disorders 2Schizophrenia not a single disease but multiple genetically distinct disorders 3Schizophrenia not a single disease but multiple genetically distinct disorders 4Schizophrenia not a single disease but multiple genetically distinct disorders 5The biomethane market needs clear frame conditions for further growth 2The biomethane market needs clear frame conditions for further growth 3Global Fingerprint Lock Industry Report 2014 2
... planet,s tiniest inhabitants may help address two of society,s ... vast quantities of organic waste produced and where to ... Torres and Sudeep Popat, researchers at Arizona State University,s ... converting waste into useful energy. These microorganisms are ...
... more than 272,000 maternal deaths from childbirth each year, ... the Johns Hopkins Bloomberg School of Public Health. Researchers ... contraception could reduce maternal deaths an additional 30 percent. ... Lancet as part of a series of articles ...
... Models & Mechanisms, one-day symposium entitled Protein-Folding Diseases: ... Symposium will focus on how misfolded proteins contribute ... and whole-organism level, highlighting the diverse biological models ... It is becoming increasingly clear that protein misfolding ...
Cached Biology News:Waste to watts: Improving microbial fuel cells 2Waste to watts: Improving microbial fuel cells 3Waste to watts: Improving microbial fuel cells 4Contraceptive use averts 272,000 maternal deaths worldwide 2
Anti-Salmonid Ig (H), Alk Phos, (Clone IPA5F12) (mouse IgG2a)...
Rat monoclonal [HK5.3] to B7 RP1 (Phycoerythrin) ( Abpromise for all tested applications). entrezGeneID: 23308 SwissProtID: O75144...
... the HECT protein, E6-AP and ... suggests that this E2 is ... of non-""N-end rule"" protein substrates ... proteins as well as the ...
NANS Immunogen: NANS (NP_061819, 260 a.a. ~ 360 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Biology Products: